RBC Capital maintains Outperform rating on Nurix Therapeutics, $35 price target
RBC Capital maintained an Outperform rating on Nurix Therapeutics with a $35 price target, suggesting a 57.9% upside from the Oct 12 close. The firm cited encouraging clinical data for bexobrutideg and a strong pipeline with a $1.1 billion cash position. Recent analyst price targets range from $32 to $34.
How this was made
The 30-second read
Why it matters
The upgrade could lead to modest buying pressure, but the lack of fresh catalyst limits impact.
Market read
A rating maintenance with a higher price target provides a modest trade signal for NRIX.
What to watch
No new clinical data released; the rating is based on existing information.
Background
RBC Capital's analyst note reiterates confidence in Nurix's pipeline and cash position.
Ticker impact
RBC Capital maintained an Outperform rating on Nurix Therapeutics and set a new $35 price target, implying a 57.9% upside.
likely upward pressure as investors price in the higher target
The rating change is a fresh analyst action; no other catalyst is mentioned.
Market effects
May boost sentiment in the biotech/TPD sector as a peer receives a strong rating.
Limited to US biotech investors.
Low
Counterpoint
The price target may be overly optimistic given early-stage trial data.
Key entities
- CompanyNurix Therapeutics
Biotech firm developing targeted protein degradation therapies.
- AnalystRBC Capital
Investment bank providing the rating and price target.
